Immunology Topic Homepage

Learning Zones

,Lernbereich symptomatisches Asthma

Dieses Fortbildungsmaterial wurde für Gesundheitsexperten in Europa, die mit der Versorgung von Asthma-Patienten betraut sind, entwickelt.

Mehr Bewusstsein für die Krankheit - Dieser Bereich liefert Hintergrundinformationen zu den Auswirkungen des symptomatischen Asthmas und klärt über potenzielle Behandlungsstrategien auf.

RCGP-akkredierte CME - Im Rahmen der Maßnahmen zur kontinuierlichen berufsbegleitenden Fortbildung für Ärzte (CME) können Sie mehr über die Behandlung des symptomatischen Asthmas in der Praxis aus der Perspektive der Ärzte erfahren. In vier Runden erörtern Richard Russell und Thys van der Molen folgende Themen:

  1. Was ist Asthmakontrolle: Wer, warum und wie viele?
  2. Verbesserung der Asthmakontrolle in der Gemeindeversorgung
  3. Derzeitige Standardbehandlung bei Asthma
  4. Pro und Contra zusätzlicher Add-on-Therapien

Wenn Sie den Evaluierungsfragebogen vollständig ausfüllen, wird Ihnen eine Stunde für Ihr CPD-Zertifikat angerechnet.

SPIRIVA® Respimat® ist in der Europäischen Union, Japan, USA und vielen anderen Ländern für die Anwendung bei Asthma zugelassen. Die Indikation ist von Land zu Land verschieden. Dieses Fortbildungsmaterial kann daher Informationen über Medikationen enthalten, für die in Ihrem Land möglicherweise keine Indikationen zugelassen sind.

,Zone d’apprentissage de l’asthme symptomatique

Ces ressources pédagogiques ont été développées pour les professionnels de la santé en Europe, impliqués dans la prise en charge de patients asthmatiques.

Sensibilisation à la maladie – Cette section fournit des informations générales à propos de l’impact de l’asthme symptomatique et de stratégies de prise en charge potentielles.

FMC accréditée par le RCGP – Au sein des activités de Formation Médicale Continue (FMC), vous aurez accès aux perspectives de médecins sur la prise en charge pratique de l’asthme symptomatique. Richard Russell et Thys van der Molen abordent ce sujet au cours de quatre sessions :

  1. Qu’est-ce que le contrôle de l’asthme: qui, pourquoi et combien ?
  2. Améliorer le contrôle de l’asthme dans la communauté
  3. Traitement actuel standard de l’asthme
  4. Avantages et inconvénients de traitements d’appoint supplémentaires

Répondez au questionnaire d’évaluation et une heure sera ajoutée à votre DPC.

SPIRIVA® Respimat® est approuvée contre l’asthme dans l’Union Européenne, le Japon, les Etats-Unis et de nombreux autres pays. Les indications varient d’un pays à l’autre et les ressources pédagogiques peuvent contenir des informations sur des médicaments dont les indications ne sont pas approuvées dans votre pays.

,Área de aprendizagem sobre a asma sintomática

Este recurso educativo foi desenvolvido para profissionais de saúde na Europa envolvidos na prestação de cuidados a doentes asmáticos.

Sensibilização para a doença – Esta secção apresenta informações de referência relativas ao impacto da asma sintomática e a potenciais estratégias de gestão.

FMC acreditada pelo RCGP – No âmbito da atividade de formação médica contínua (FMC), pode tomar conhecimento das perspetivas dos médicos a respeito da gestão da asma sintomática na prática. Richard Russell e Thys van der Molen discutem em quatro sessões:

  1. Em que consiste o controlo da asma: quem, porquê e quantos?
  2. Melhorar o controlo da asma na comunidade
  3. Tratamento atual de referência para a asma
  4. Vantagens e desvantagens do tratamento complementar adicional

Ser-lhe-á creditada uma hora de DPC se responder com sucesso ao questionário de avaliação

O SPIRIVA® Respimat® está aprovado para utilização na asma na União Europeia, no Japão, nos EUA e em muitos outros países. A indicação varia em função do país e o recurso educativo poderá conter informação sobre medicamentos cujas indicações poderão não estar aprovadas no seu país.

,Zona de aprendizaje sobre el asma sintomática

Este recurso educativo ha sido elaborado por profesionales sanitarios de Europa que intervienen en la atención de pacientes con asma.

Concienciación sobre la enfermedad: Esta sección proporciona información general relativa al impacto del asma sintomática y a las posibles estrategias de tratamiento.

EMC homologada por el RCGP: Como parte de la actividad de educación médica continuada (EMC), puede aprender sobre las perspectivas de los médicos sobre el tratamiento del asma sintomática en la práctica clínica. Richard Russell y Thys van der Molen comentan en cuatro sesiones:

  1. Qué es el control del asma: ¿quién, por qué y cuántos?
  2. Mejorar el control del asma en el ámbito extrahospitalario
  3. Tratamiento de referencia actual para el asma
  4. Ventajas e inconvenientes del tratamiento complementario adicional

Se concederá una hora para la consecución de su crédito de DPP tras haber superado con éxito el cuestionario de evaluación.

SPIRIVA® Respimat® está autorizado para su uso en el asma en la Unión Europea, Japón, EE. UU. y muchos otros países. La indicación varía según el país y este recurso educativo puede contener información sobre medicamentos que no estén aprobados en su país para las indicaciones mencionadas.

,Spazio di apprendimento sull’asma sintomatico

Queste risorse didattiche sono state sviluppate per i professionisti del settore sanitario europei che operano nel campo dell’assistenza ai pazienti affetti da asma.

Sensibilizzazione – Questa sezione fornisce informazioni generali sugli effetti dell’asma sintomatica e sulle potenziali strategie di gestione.

CME accreditata dall'RCGP – All’interno delle attività di educazione medica continua (CME), puoi scoprire le prospettive mediche per la gestione pratica dell’asma sintomatica. Richard Russell e Thys van der Molen discutono in quattro sessioni di:

  1. Cos’è il controllo dell’asma: chi, perché e quanti?
  2. Migliorare il controllo dell’asma nella comunità
  3. L’attuale trattamento standard dell’asma
  4. Pro e contro dellla terapia aggiuntiva.

Il CPD (Sviluppo Professionale Continuo) ti sarà riconosciuto un’ora dopo, dietro superamento del questionario valutativo.

SPIRIVA® Respimat® è autorizzato per la cura dell’asma nell’Unione Europea, in Giappone, negli Stati Uniti e in molti altri Paesi. Le indicazioni variano da Paese a Paese e le risorse didattiche possono contenere informazioni su farmaci le cui indicazioni potrebbero non essere approvate nel tuo Paese.

,Symptomatic Asthma Learning Zone

This educational resource has been developed for healthcare professionals in Europe who are involved in the care of patients with asthma.

Disease Awareness - This section provides background information regarding the impact of symptomatic asthma and potential management strategies.

RCGP-accredited CME - Within the continuing medical education (CME) activity, you can learn about physician perspectives on managing symptomatic asthma in practice. Richard Russell and Thys van der Molen discuss in four sessions:

  1. What is asthma control: Who, why and how many?
  2. Improving asthma control in the community
  3. Current standard asthma treatment
  4. Pros and cons of additional add-on treatment.

One hour towards your CPD will be rewarded upon successful completion of the evaluation questionnaire

SPIRIVA® Respimat® is approved for use in asthma in the European Union, Japan, USA and many other countries. The indication varies by country and the educational resource may contain information about medications for which indications may not be approved in your country.

,

Psoriasis is a chronic inflammatory disease affecting approximately 2% of the world’s population. The Psoriasis Knowledge Centre provides dermatologists, family medicine doctors and other healthcare professionals with relevant information including epidemiology, pathophysiology, diagnosis and more.

A treatment section reviews the established treatments available for psoriasis and considers their modes of action, available clinical data and place in the therapeutic pathway.

Also located within the Psoriasis Knowledge Centre is a dedicated educational section focusing on IL-17A in Psoriasis. This free resource is intended to provide healthcare professionals with information on the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.

,

The Chronic Spontaneous Urticaria (CSU) Knowledge Centre has been developed to address the current lack of early diagnosis of this condition. Urticaria is more common than previously thought and studies suggest chronic urticaria affects up to 1% of the population at any given time with CSU responsible for two-thirds of these cases.

Allergists, immunologists, dermatologists and other healthcare professionals involved in the management of CSU will find a range of content to support you in effectively diagnosing and treating the condition.

In this resource, you will find a disease overview, symposia highlights platform, video channel and additional resources including an events calendar and useful external links.

Recent additions to this resource are faculty video presentations from the Novartis-sponsored CSU symposium at WCD 2015 and expert slides discussing real-life patient case studies. The case studies explore how treatment recommendations in the recent best-practice guidelines can be applied in the dermatology clinic.

,IL-17A Header

Located within the Psoriasis Knowledge Centre, IL-17A in Psoriasis has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.

Content is arranged within multiple sections that are easy to navigate. Users can find expert videos, clinical slide decks on topics such as disease pathophysiology and emerging therapies, congress highlights, key publications and links to useful resources.

This free resource is intended for healthcare professionals involved in the treatment and management of patients with psoriasis.

This resource has been developed in collaboration with Novartis Pharma AG.

Clinical Case Studies

Bloody Diarrhoea (E. coli O157)

Infection: Gastrointestinal Infection

Stephanie Dundas, Consultant in Infectious Diseases and General Medicine, Monklands General Hospital, NHS Lanarkshire, Airdrie, UK

Case History
A 67-year-old woman was admitted to the surgical ward with a 72-hour history of increasingly severe abdominal pain and bloody diarrhoea. The referral from the general practitioner indicated a known history of diverticular disease, hypertension and ischaemic heart disease.

Pulmonary Arteriovenous Malformation

Respiratory Medicine & Allergy: Pulmonary Vascular Diseases

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK

Case History
A 45-year-old lady was referred to the chest clinic because of dyspnoea. She had gradually become more breathless over two years and was now breathless at rest.

Latest News

Blog

The 2003 British Thoracic Society and Scottish Intercollegiate Guidelines Network asthma management guidelines use the international consensus definition to describe asthma as:
“a chronic inflammatory disorder of the airways. In susceptible individuals inflammatory symptoms are usually associated with widespread but variable airflow obstruction and an increase in airway response to a variety of stimuli. Obstruction is often reversible either spontaneously or with treatment”.

During an asthma attack, also called an asthma exacerbation, airways become swollen and inflamed. The muscles around the airways contract narrowing the bronchial tubes.
Asthma attacks can be minor which improve with home treatment, or severe which can become a life threatening emergency.

This post discusses clinical assessment and treatment of patients with acute asthma exacerbations.

Medical Videos

An Animation of The Main Roles of the Immune System
An Animation of The Main Roles of the Immune System
An Animation Demonstrating the Role of Natural Killer Cells
An Animation Demonstrating the Role of Natural Killer Cells

Recent Drug Updates

Medical Journal Abstracts on Immunology

Psoriasis

-167 days ago -  Psoriasis

This review emphasizes the pathologic features of psoriatic lesions, recent genetic studies of psoriasis, and immunologic factors in the disease. The evolution of a psoriatic lesion entails a ...

Imatinib: a breakthrough of targeted therapy in cancer.

-95 days ago -  Imatinib: a breakthrough of targeted therapy in cancer.

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach ...

Medical Images

Choroidal tubercules
Choroidal tubercules
Pneumocystis
Pneumocystis
Regeneration hyperplasia
Regeneration hyperplasia
Key events leading up to the era of HAART
Key events leading up to the era of HAART
AIDS retinopathy
AIDS retinopathy
PCP pneumocystis pneumonia
PCP pneumocystis pneumonia
Circumscribed right frontal lobe ring-enhancing lesion
Circumscribed right frontal lobe ring-enhancing lesion
Fibroscan (TM)
Fibroscan (TM)
Bacterial pneumonia
Bacterial pneumonia
Hypersensitivity rash
Hypersensitivity rash

Clinical Guidelines

Myeloma: diagnosis and management

Feb 2016

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and..

... primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

This guideline includes recommendations on:
   - communication and support
   - laboratory investigations
   - imaging investigations
   - managing newly-diagnosed and relapsed myeloma
   - preventing and managing bone disease and other complications
   - monitoring

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Aug 2015

Chronic lymphocytic leukaemia is the most common leukaemia in the Western world and generally..

... affects older populations. These updated ESMO Clinical Practice Guidelines present the latest information on CLL including the diagnosis and molecular biology of CLL and treatment strategies for early and advanced disease.

Online CME

Biological treatment for inflammatory arthritis

After completing this module, you should be able to: know what biological treatments are, be able to explain to patients how they work, know what conditions they are used for,...

Myasthenia gravis: a guide to diagnosis and treatment

After completing this module you should be able to: make a clinical diagnosis of myasthenia gravis, select appropriate diagnostic tests to confirm your diagnosis, and understand the principles of therapy...

Clinical Trials

Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial (Hypogamma Int1)

-77 days ago

The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with hypogammaglobulinemia ...

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

-16 days ago

Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection ...

Back to top